左甲状腺素钠联合复方丹参滴丸治疗桥本甲状腺炎的临床疗效及对自身免疫抗体的影响

Compound Danshen dropping pill for the treatment of Hashimoto's thyroiditis and its effect on autoimmune antibodies

目的:探讨左甲状腺素钠联合复方丹参滴丸治疗桥本甲状腺炎(HT)的临床疗效及对自身免疫抗体的影响。方法:将2014—2016年在本院就诊的142例HT患者按照不同的治疗方式,分为对照组(单用左甲状腺素钠治疗)和观察组(左甲状腺素钠联合复方丹参滴丸治疗),每组71例。比较两组临床疗效及治疗前、后患者甲状腺功能、自身免疫抗体、甲状腺肿大改善情况及药物不良反应发生率等差异。结果:观察组治疗有效率为84.5%,高于对照组的46.5%(P<0.01);治疗后,观察组的血清促甲状腺激素(TSH)、游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、甲状腺球蛋白抗体(TGAb)及甲状腺过氧化物酶抗体(TPOAb)水平改善优于对照组(P<0.05),同时,观察组在左叶、峡部及右叶的甲状腺肿大改善情况亦优于对照组(P<0.05);两组患者在治疗期间均未出现药物不良反应。结论:复方丹参滴丸有利于改善HT患者甲状腺功能、下调甲状腺自身免疫性抗体水平和缩小甲状腺体积,临床疗效显著。

Objective： To investigate the clinical efficacy of compound Danshen dropping pills in the treatment of Hashimoto＇s thyroiditis （HT） and its effect on autoimmune antibodies. Methods： A total of 142 HT patients treated in our hospital from 2014 to 2016 were enrolled, and randomly divided into a control group and an obser- vation group, with 71 cases in each group. The patients in the control group received levothyroxine sodium, and those in the observation group received levothyroxine sodium combined with Danshen dropping pills. The clinical efficacy, thyroid function, autoimmune antibodies, goiter and the incidence of adverse reactions were ob- served and compared. Results： The effective rate was 84. 5% in the observation group, which was higher than that in the control group （46. 5% ） （P〈0.01）. After treatment, the improvement of serum thyroid stimulating hormone （TSH）, free triiodothyronine （FT3）, free thyroxine （FT4）, thyroglobulin antibody （TGAb） and thy- roid peroxidase antibody （TPOAb） of the observation group was better than that of the control group （P〈0.05）. Meanwhile, the improvement of thyroid enlargement in the left lobe, isthmus and right lobe in the observation group was also greater than that in the control group （P〈0. 05）. No adverse reactions was noted in both groups. Conclusion： Compound Danshen dropping pills was effective in the treatment of HT. It could improve thyroid function, reduce the level of thyroid autoimmune antibodies and shrink the thyroid volume of HT patients.